Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Repligen Corp.
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
- Research, Analytical Equipment & Supplies
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Atoll GmBH
- C Technologies, Inc.
- Novozymes Biopharma Sweden AB
- TangenX Technology Corporation
- Polymem S.A.